Trabalhando juntos e procurando sempre a excelência no desenvolvimento de agentes de base biológica para produtos farmacêuticos e cosméticos que respondam às necessidades humanas e respeitem o meio ambiente
SOLFARCOS – Pharmaceutical and Cosmetic Solutions Ltd. was created in 2016 as a spin-off company of the University of Minho to exploit technologies developed by the Bioprocess and Bionanotechnology Research Group (BBRG) of the Biological Engineering Center. Today, SOLFARCOS employs 8 researchers and supports 3 PhD students working in 5 research lines – Pharmaceutical Line, Hair Care, Skin Care, Protein Engineering and Peptide Technology – and 2 cross-cutting areas – Chemical Synthesis & Analysis, and Project Management, Technologies & Regulatory Affairs.
SOLFARCOS is dedicated to the development and commercialization of biobased technologies for pharmaceutical and cosmetic applications for incorporation into third party portfolios (B2B strategy). Our team of R&D specialists in the fields of Biotechnology, Health and Nanomedicine also provides consulting and management services in support of European projects in the field of Nanomedicine. Currently, the company’s turnover comes from marketing proprietary peptides for hair applications. The revenues are fully invested in R&D activities and a significant part will be used to promote the proof-of-concept clinical trial that will be conducted in the first half of 2022 to test the efficacy, safety, and tolerability of a methotrexate-based liposomal formulation with targeted release in rheumatoid arthritis patients. This study is consequential to the first human clinical trial, which successfully ended in September 2021, representing a significant milestone of the team’s commitment that has lasted for more than 10 years and has had more than 10 million euros of EU contribution obtained through the Nanofol and Folsmart projects.
In addition to the R&D laboratory located at the headquarters, SOLFARCOS has full access to the facilities of the Biological Engineering Center of the University of Minho. Recently a new space of more than 2,000m2 was acquired where a complete industrial unit for the in-house production of proprietary proteins and peptides will grow.